Phaarmasia Profit & Loss Annual

BSE: 523620 | NSE: - | ISIN: INE486I01016 | Sector: Biotechnology & Drugs

85.00 0.00 (0.00%)Updated : 16 Sep 2026

Research on

Interim Data

Annual Data

Fiscal Period	2026	2025	2024	2023
Period End Date	Mar 26	Mar 25	Mar 24	Mar 23
Total Operating Expense	45.55	26.70	31.76	29.39
Other Net	0.92	0.74	0.64	0.50
Diluted Weighted Average Shares	0.68	0.68	0.68	0.68
Gain( Loss)on Saleof Assets	18.99	-	-	-
Depreciation/ Amortization	0.21	0.32	0.34	0.36
Operating Income	1.66	-2.33	-1.16	-1.90
Net Income	17.57	-1.59	-0.52	-1.26
Income Availableto Com Excl Extra Ord	17.57	-1.59	-0.52	-1.26
Other Operating Expenses Total	8.94	5.01	5.05	4.94
Net Income Before Taxes	21.39	-1.60	-0.55	-1.43
Net Income After Taxes	17.57	-1.59	-0.52	-1.26
Income Availableto Com Incl Extra Ord	17.57	-1.59	-0.52	-1.26
Costof Revenue Total	33.50	19.46	24.61	22.46
Gross Profit	13.70	4.91	5.99	5.03
Interest Inc( Exp) Net- Non- Op Total	-0.17	-0.01	-0.02	-0.03
Diluted Net Income	17.57	-1.59	-0.52	-1.26
Provisionfor Income Taxes	3.82	-0.01	-0.03	-0.17
period Type	-	-	-	-
Net Income Before Extra Items	17.57	-1.59	-0.52	-1.26
Total Revenue	47.21	24.37	30.59	27.49
period Length	12.00	12.00	12.00	12.00
Revenue	47.21	24.37	30.59	27.49
Selling/ General/ Admin Expenses Total	2.89	1.91	1.76	1.64
Diluted Normalized EPS	2.89	-2.33	-0.76	-1.84
Diluted EPS Excluding Extra Ord Items	25.74	-2.33	-0.76	-1.84
Total Adjustmentsto Net Income	-	-	0.00	-